Related Experiment Video

Updated: Jul 9, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Markers predicting clinical benefit in breast cancer from microtubule-targeting agents

L Pusztai1

  • 1Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77230-1439, USA. lpusztai@mdanderson.org

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 10, 2008
PubMed

Insights

Taxanes and epothilones target microtubules, but patient response varies. Biomarkers like betaIII-tubulin may predict sensitivity to specific agents, guiding personalized breast cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Taxanes and epothilones are microtubule-targeting agents used in cancer therapy.
  • Despite similar mechanisms, clinical data suggest partial non-cross resistance between these drug classes and individual agents.
  • Identifying predictive biomarkers is crucial for optimizing treatment selection in breast cancer patients.

Purpose of the Study:

  • To explore potential biomarkers that predict patient response to taxanes and epothilones.
  • To investigate the role of specific molecular markers in differential sensitivity to paclitaxel and ixabepilone.

Main Methods:

  • Review of in vitro and clinical data on taxane and epothilone resistance mechanisms.
  • Analysis of biomarkers including P-glycoprotein, beta-tubulin mutations, betaIII-tubulin overexpression, estrogen receptor status, tau expression, and HER2 amplification.
  • Pharmacogenomic analysis to identify novel predictive markers.

Main Results:

  • P-glycoprotein and beta-tubulin mutations are linked to taxane resistance, not epothilone resistance.
  • BetaIII-tubulin overexpression is associated with taxane resistance but not ixabepilone sensitivity.
  • Estrogen receptor negativity, low tau, and HER2 amplification may indicate paclitaxel sensitivity.
  • Pharmacogenomic analysis identified potential markers for differential sensitivity.

Conclusions:

  • Biomarkers like betaIII-tubulin show promise in predicting differential sensitivity to taxanes and epothilones.
  • Personalized treatment strategies may be improved by utilizing these molecular markers.
  • Further clinical validation of identified pharmacogenomic markers is necessary.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...